Recent studies have identified Dock5 as a key regulatory molecule in podocyte lipotoxicity: Dock5 deficiency exacerbates podocyte damage in proteinuria-associated nephropathies by inhibiting Rac1 GTPase activation and disrupting cytoskeletal stability, suggesting it may be a potential therapeutic target (87). This evidence concerns the gene DOCK5 and kidney disorder.